← Eichor
Study identifier: NCT03676868 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations

Condition: Cerebral Arteriovenous Malformations · Ruptured or Unruptured Cerebral Arteriovenous Malformations  ·  Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

PhaseN/A
Planned participants300
Who can joinAll sexes, 0 Years to no upper limit
Healthy volunteersNo

About this study

The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation. The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke. The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.

This description comes directly from the study's public registry record.

Talk to the study team

Amélie Yavchitz  ·  01 48 63 64 54  ·  ayavchitz@for.paris

Jean Philippe DESILLES  ·  jp.desilles@for.paris

Always discuss trial participation with your own doctor first.

Locations (1)

Fondation Ophtalmologique RotschildParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03676868